Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
November 25, 2024 17:35 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
November 14, 2024 17:30 ET
|
Firefly Neuroscience, Inc.
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s...
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider
November 11, 2024 11:45 ET
|
SNS Insider pvt ltd
Austin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- “According to S&S Insider, The Neuroscience Market Size was valued at USD 35.3 billion in 2023 and is projected to reach to USD 50.2 billion by 2032,...
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
November 06, 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Arvinas to Participate in Upcoming Investor Conferences
November 04, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 30, 2024 07:00 ET
|
Arvinas Inc.
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 25, 2024 16:10 ET
|
Firefly Neuroscience, Inc.
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference
October 24, 2024 09:00 ET
|
NeuroOne Medical Technologies
NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
October 22, 2024 16:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
October 21, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...